The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 14th year, is a unique and exciting multidisciplinary program. The Congress is the premiere global meeting dedicated to diabetes, obesity, metabolism, and energy balance, linking research to clinical practice, and highlighting our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

For more than a decade, the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) has brought researchers, physicians, and other clinicians & healthcare professionals together for a distinctive international program that bridges bench to bedside. WCIRDC offers attendees a unique experience where they may interact with the distinguished global faculty to experience a program which promotes a new understanding of metabolic diseases, facilitates the development of future therapeutic modalities, and implements the management of obesity and diabetes by focusing on lifestyle and beyond and by evaluating contemporary medications, devices, and surgeries used in preventing CVD and other complications.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance (IR), diabetes, and cardiovascular disease (CVD), the Congress’ focus has expanded to evaluating both clinical and basic science aspects of diabetes, obesity, and CVD, focusing beyond insulin resistance and hyperinsulinemia on obesity, the fat cell, incretins, the kidney and energy metabolism, cardiovascular complications, and cancer. The Congress further addresses lipid abnormalities, hypertension, and hypercoagulation. The goal is to understand the pathophysiology and the epidemic of obesity and diabetes, and to develop appropriate comprehensive clinical management plans.

Highlights of this year’s program:

• Lifetime Achievement Award Presentation and Keynote Address: Gerald Reaven, MD.
• Distinguished Leader in Insulin Resistance Award and Lecture: Arun J. Sanyal, MD.
• Special Symposia: State of the Art of Incretin Therapy: Daniel Drucker, MD, and Jens J. Holst, PhD
• The Scientific Approach to Personalized Medicine in the Management of Diabetes: Focus on Nutrition, Exercise and Individualized Pharmacotherapy;
• Medications in the Pipeline: Obesity, Diabetes, and Other Metabolic Disorders.
• Other highlights: Congestive Heart Failure, Lipids and Atherosclerosis, and Thrombosis.
• Management of Obesity- pharmacological agents, Endoscopic Therapy and bariatric surgery.

For primary care clinicians, the Congress will feature a series of workshops and “meet the expert” panels addressing the clinical management of kidney disease, diabetes, obesity, lipids, the high risk CVD patients and more. To make basic and clinical research topics in metabolism, vascular biology, obesity and diabetes relevant to clinical medicine, there will be commentaries on its clinical implications by recognized clinical experts. The strength and advantage of the Congress is through its intimate setting that promotes personal and direct contact between participants and the distinguished faculty.

The Congress attracts state-of-the-art abstracts from around the globe. These abstracts will be published in Endocrine Practice, the official journal of the American Association of Clinical Endocrinologists (AACE). Typically, articles about the meeting are published in several medical journals, such as Endocrine Practice, Metabolism, The Journal of Diabetes, and Diabetes Care.

Overall Program Objectives

The program is designed to evaluate both the clinical and basic science aspects of diabetes, obesity, and CVD, by focusing on insulin resistance, hyperinsulinemia, fat cell, incretins, gut hormones, the kidney, and energy metabolism. The goal is to understand its pathophysiology, and to develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

•  Provide comprehensive management of diabetes, addressing obesity, hypertension, dyslipidemia, as well as glucose
• Discuss the role of obesity in the development of cardiometabolic conditions
• Discuss the role of incretins in the management of obesity, diabetes, and their complications
• Evaluate the extent of macrovascular and microvascular disease in diabetes and obesity
• State the risks and health issues of heart disease in patients with diabetes
• Explain the role of lipids, in particular low-density lipoprotien (LDL-C) and non- HDL-C, in the development of atherosclerosis
•  Understand the role of PCSK9 and the newly developed monoclonal antibodies- the PCSK9 inhibitors in LDL homeostasis and the contemporary approach to management and prevention of CVD
•  Describe contemporary approaches to congestive heart failure
• Explain the relationship of the kidney to diabetes & CVD
• Design appropriate management plans for Diabetes, incorporating insulin with incretins
• Explain the roles of diabetes and insulin resistance in the development of kidney disease, retinopathy, and CVD
•  Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD
• Learn the role of SGLT2i in the management of diabetes and its potential complications.
• Evaluate bariatric surgery procedures and newly-developed procedures, as well as devices and their effect on weight loss and hormones, and their long-term outcomes